TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32702911
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with transcranial direct current stimulation (tDCS) and computerized cognitive rehabilitation treatment (CCRT)
Study: 32702911
Drug: Computerized cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive rehabilitation treatment (CCRT) alone
Study: 32702911
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with EA and CCRT
Study: 32702911
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with tDCS and CCRT
Study: 33039154
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels ≤16 ng/mL for GDM
Study: 33039154
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels 16–26 ng/mL for GDM
Study: 33039154
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels >26 ng/mL for GDM
Study: 33039154
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels ≤15 ng/mL for preterm delivery
Study: 33039154
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels 15–21 ng/mL for preterm delivery
Study: 33039154
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels >21 ng/mL for preterm delivery
Study: 33039154
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels ≤15 ng/mL for preeclampsia
Study: 33039154
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels 15–23 ng/mL for preeclampsia
Study: 33039154
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D levels >23 ng/mL for preeclampsia
Study: 35994896
Drug: Menopausal hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Menopausal hormone therapy (MHT) containing 1 or 2 mg of estradiol and cyclical 10 mg dydrogesterone for one year
Study: 36124667
Drug: Weekly exercise
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly exercise
Study: 32823594
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg·kg−1·body mass)
Study: 33861384
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavioral therapy (CBT) for OCD, 14 weekly sessions
Study: 32354152
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g PHGG up to three times per day for 3 weeks
Study: 34420375
Drug: Venlafaxine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (1 mg/kg for 60 days)
Study: 34851411
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg per day intranasal OP0201 for 10 days
Study: 34426106
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg, subcutaneous, once)
Study: 34914294
Drug: Yishen Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yishen Huoxue Decoction (1 dose a day, twice daily for 3 months)
Study: 34914294
Drug: Shengjing Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengjing Tablets (4 tablets once, tid) combined with L-carnitine oral solution (10 ml, bid for 3 months)
Study: 32787925
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed therapy (DOT)
Study: 33662951
Drug: Individualized homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized homeopathic medicines (IH) plus psychological counseling (PC)
Study: 32768154
Drug: Cathodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal tDCS with 3 mA and low dosage of flunarizine (2.5 mg)
Study: 32768154
Drug: Cathodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal tDCS with 3 mA and medium dosage of flunarizine (5 mg)
Study: 32768154
Drug: Cathodal tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathodal tDCS with 3 mA and high dosage of flunarizine (10 mg)
Study: 34187460
Drug: Guided self-study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-study (G‐SS)
Study: 34954406
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil therapy
Study: 34967899
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine liposome suspension block + oral placebo (BUP)
Study: 34967899
Drug: Lidocaine block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine block + oral placebo (LID)
Study: 34967899
Drug: Lidocaine block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine block + oral meloxicam (1 mg/kg) (LID + MEL)
Study: 34967899
Drug: Saline block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline block + oral placebo (CON)
Study: 35992984
Drug: Platelet Rich
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet Rich Plasma Injection (Group I)
Study: 34228393
Drug: Oral‐B 3D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral‐B 3D White Luxe/Procter & Gamble (WL)
Study: 32933348
Drug: Compassion-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion-focused therapy (CFT) - 8 sessions
Study: 33878858
Drug: Pulse-steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-steroid treatment (250 mg/day methyl-prednisolone)
Study: 33878858
Drug: High-dose steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose steroid treatment (6 mg/day dexamethasone equivalent)
Study: 33878858
Drug: Standard-care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-care therapy alone
Study: 38124551
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel
Study: 32875492
Drug: Double VEGF/HGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double VEGF/HGF gene therapy
Study: 36428274
Drug: Sham Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Therapy (ST)
Study: 36349758
Drug: S‐methyl‐L‐thiocitrulline (nNOS
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐methyl‐L‐thiocitrulline (nNOS inhibitor)
Study: 33789252
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received no intervention, only routine treatment.
Study: 32326719
Drug: Daily outdoor
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily outdoor time for more than 1 hour
Study: 35465297
Drug: Intermittent docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent docetaxel chemotherapy guided by circulating methylated glutathione S-transferase Pi-1 (mGSTP1)
Study: 35465297
Drug: Continue docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continue docetaxel 75 mg/m2 q3w in accordance with clinician’s usual practice
Study: 33853721
Drug: shamTMS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: shamTMS group (sham treatment)
Study: 35028668
Drug: Lenacapavir (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenacapavir (up to 750 mg, single dose)
Study: 35028668
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 day monotherapy)
Study: 36031718
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg ethanol
Study: 38286618
Drug: Acetazolamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (500 mg)
Study: 33726843
Drug: Electronic prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic prompt embedded in a Clinical Decision Support System (CDSS) for Screening, Brief intervention, and Referral to Treatment (SBIRT)
Study: 36348476
Drug: 0.15 g/Kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 g/Kg C-IVIG with standard of care (SOC)
Study: 32725073
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid therapy
Study: 35959833
Drug: Changing nasogastric
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changing nasogastric feeding tubes daily during the first week of life
Study: 35959833
Drug: Changing nasogastric
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changing nasogastric feeding tubes weekly (on day seven)
Study: 33000618
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 deficiency (<20 ng/mL)
Study: 34049919
Drug: Other immunosuppressants
Normalized name: Other immunosuppressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other immunosuppressants (including mycophenolate mofetil)
Study: 34049919
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment specified
Study: 33663487
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) and sulfasalazine (SSZ) for the first 12 weeks, then remove TNFi but continue other treatments for the next 48 weeks.
Study: 33663487
Drug: Maintain TNFi
Normalized name: mountain pepper whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintain TNFi + MTX for the first 12 weeks, then remove TNFi but continue MTX monotherapy for the next 48 weeks.
Study: 33663487
Drug: Incremental cost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental cost per reducing 1 case of relapse; patient reported intolerance to the treatment; adverse events; change of mean disease activity measured by DAS28, CDAI, and SDAI; the proportion of modified Sharp score increase < 0.3; ultrasound-detected remission in hands; Health Assessment Questionnaire Disability Index (HAQ-DI); health-related quality of life (EQ-5D-5L and SF-6D).
Study: 32068484
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg vibegron
Study: 32068484
Drug: Extended-release 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release 4 mg tolterodine
Study: 36227170
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PMT and CPS)
Study: 33097351
Drug: Diazepam 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.1 mg/kg plus fentanyl 1 μg/kg IV
Study: 33097351
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg plus fentanyl 1 μg/kg IV
Study: 35101115
Drug: Monthly (28-day)
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly (28-day) INJ-BUP
Study: 35101115
Drug: Daily SL-BUP/NLX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SL-BUP/NLX
Study: 35436231
Drug: Oral antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotics
Study: 32881968
Drug: ALFA-adjuvanted vaccine
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALFA-adjuvanted vaccine
Study: 39083587
Drug: Alum-adjuvanted vaccine
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alum-adjuvanted vaccine
Study: 32007099
Drug: Model-based PEEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model-based PEEP titration
Study: 32035487
Drug: Alirocumab 75
Normalized name: alirocumab 75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 75 mg every 2 weeks (Q2W) with possible increase to 150 mg Q2W at Week 12
Study: 32035487
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (ezetimibe, fenofibrate, or no additional lipid-lowering therapy)
Study: 35426822
Drug: Gelfoam carrier
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelfoam carrier soaked in 1 ml of triamcinolone acetonide (40 mg)
Study: 34445031
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula containing 5HMO-Mix (5.75 g/L total, comprising 52% 2′‐fucosyllactose, 13% 3‐fucosyllactose, 26% lacto‐N‐tetraose, 4% 3′‐sialyllactose, and 5% 6′‐sialyllactose)
Study: 36323130
Drug: Zonisamide 25
Normalized name: zonisamide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 25 mg add-on
Study: 35565903
Drug: Moringa oleifera
Normalized name: Moringa Oleifera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moringa oleifera (MO) dry leaf powder, 6 × 400 mg capsules/day for 12 weeks
Study: 33001135
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (arm A)
Study: 33001135
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (arm B)
Study: 33001135
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks (arm C)
Study: 32358807
Drug: Inhaled dry
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dry powder mannitol
Study: 35852013
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ca (OH)2 and Allium sativum
Study: 32267348
Drug: Vildagliptin added
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Vildagliptin added to insulin therapy
Study: 32267348
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued insulin therapy)
Study: 37352880
Drug: Inactivated vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated vaccine
Study: 32843496
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy plus coronary artery bypass graft surgery (CABG)
Study: 32955088
Drug: RZF 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZF 400 mg QWk
Study: 32955088
Drug: RZF 400/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZF 400/200 mg QWk
Study: 32955088
Drug: CAS 70
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAS 70 mg loading dose followed by 50 mg daily for ≤4 weeks
Study: 35968303
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication use
Study: 38547892
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events
Study: 32586434
Drug: Be a
Normalized name: Tube Attaching Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Be a Mom (self-guided web-based intervention grounded in cognitive behavioral therapy)
Study: 35645331
Drug: Nurse-led Adverse
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led Adverse Drug Reaction (ADRe) Profile
Study: 34869486
Drug: Hydroxybutyl chitosan
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxybutyl chitosan (HBC) injection
Study: 33885930
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA treatment for 24 weeks
Study: 33126317
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents (ESAs) combined with traditional Chinese medicine (TCM)
Study: 39581908
Drug: Erythropoiesis-stimulating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agents (ESAs)
Study: 36416492
Drug: Psilocybin (0.143
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (0.143 mg/kg)
Study: 32332672
Drug: Continuous adductor
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous adductor canal block (CACB) with 0.5% ropivacaine 20 mL followed by continuous infusion of 0.2% ropivacaine at 5 mL/h for 48 hours
Study: 32332672
Drug: Single‐injection adductor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐injection adductor canal block (SACB) with 0.5% ropivacaine 20 mL
Study: 32332672
Drug: Single‐injection adductor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐injection adductor canal block (SACB)
Study: 34003071
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg capsule, 1 hour before)
Study: 34003071
Drug: Placebo (cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose capsule, 1 hour before)
Study: 37941802
Drug: 10-µg/dose vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-µg/dose vaccine
Study: 37941802
Drug: 5-µg/dose vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-µg/dose vaccine
Study: 32955164
Drug: 20 IU·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU·kg bw−1 rhEpo injections every second day for 3 weeks during exposure at sea level
Study: 32955164
Drug: 20 IU·kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU·kg bw−1 rhEpo injections every second day for 3 weeks during exposure at altitude
Study: 32955164
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections at sea level
Study: 32955164
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections at altitude
Study: 36251544
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (SDF, SDF-KI, RV-SDF, RV-SDFKI)
Study: 34405256
Drug: 6-day subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-day subcutaneous GIP infusion (6 pmol kg-1 min-1)
Study: 34405256
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline [154 mmol/l NaCl])
Study: 32998143
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg monotherapy
Study: 34954841
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg 2 ml autoinjector (AI)
Study: 34954841
Drug: Secukinumab 2×
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 2× 1 ml prefilled syringe (PFS)
Study: 34954841
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg 2 ml AI
Study: 35306231
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) after multiagent chemotherapy (MA‐CTX)
Study: 32813947
Drug: Evinacumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evinacumab (15 mg/kg every 4 weeks)
Study: 35354325
Drug: Pharmacotherapy treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy treatments
Study: 35465275
Drug: Cefazolin 2
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 2 g 30-60 min before incision (Group A)
Study: 35465275
Drug: Cefazolin 2
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 2 g 30-60 min before incision and Tinidazole 1.6 g 60-120 min before incision (Group B)
Study: 34106582
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural play therapy (CBPT)
Study: 36339275
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of omega-3 fatty acids and inositol
Study: 35324094
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 50‐300 mg/d
Study: 35838110
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanate potassium suspension (200 mg/28.5 mg) under fasting conditions
Study: 35838110
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanate potassium suspension (200 mg/28.5 mg) under postprandial conditions
Study: 33580923
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost 0.005% ophthalmic solution
Study: 33580923
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone diproprionate 0.05% lotion
Study: 35262625
Drug: Prasugrel dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel dose de-escalation (5 mg daily) at 1 month post-PCI
Study: 35262625
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (10 mg daily)
Study: 34997899
Drug: Internet-Delivered Acceptance
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-Delivered Acceptance and Commitment Therapy (iACT)
Study: 32202510
Drug: PI-mono (ritonavir-boosted
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-mono (ritonavir-boosted protease inhibitors)
Study: 35318869
Drug: Crisis Counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crisis Counselling (CC)
Study: 34405305
Drug: Opioid antagonist
Normalized name: OPIOID ANTAGONIST ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid antagonist naltrexone (50 mg)
Study: 32274491
Drug: Single low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single low level laser therapy
Study: 34109364
Drug: Dexmedetomidine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1.0 μg/kg)
Study: 34109364
Drug: Midazolam +
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam + Fentanyl (0.02 mg/kg midazolam and 2.0 μg/kg fentanyl)